Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A syndrome that resembles Systemic Lupus Erythematosus both clinically and on laboratory studies may be induced by procainamide. It is associated with multisystemic involvement, positive Antinuclear Antibody titers (ANA), and positive LE cell preparations. In patients on procainamide therapy the syndrome must be differentiated from osteoarthritis, myocardial infarction, and pulmonary embolism. When procainamide is discontinued, this Lupus-like syndrome is usually reversible. Other drugs, including hydralazine and isoniazid have also been implicated in provoking this Lupus-like syndrome.
 ...
PMID:A systemic lupus erythematosus-like syndrome induced by procainamide. 72 56

Acute phase proteins are good markers of inflammatory processes. To clarify whether Serum Amyloid Protein (SAP) can be a marker for the onset of SLE disease in mice, we measured constitutive and inducible SAP levels in normal mice of different strains, in C57Bl/6 lpr/lpr (B6lpr) and [NZB x NZW]F1 (NZB/W) SLE-prone mice, in mice that develop Lupus-like syndrome during chronic Graft versus Host (GvH) reaction and in mice suffering acute GvH reaction. In comparison to B6lpr, NZB/W mice showed higher blood levels of SAP but those levels did not correlate with autoimmune parameters. In B6lpr, the SAP levels steadily increased with age and correlated with some of the parameters used for monitoring the SLE disease. High levels of SAP were also found in mice suffering acute GvH reaction whereas the lupus-like chronic GvH disease was associated with limited increase of SAP levels.
 ...
PMID:Serum amyloid protein (SAP) as a marker of autoimmune disease in mice. 775 95

Lupus-like syndrome has been described in association with various malignancies. Acute lymphocytic leukemia presenting as lupus-like syndrome has been reported in children. We report a 22-year-old male patient who developed joint and muscle ache, pleurisy, leukopenia, thrombocytopenia, fever, weight loss and was found to have positive antinuclear antibodies. Repeated peripheral smear twice did not show any abnormal cells. Six months later, bone marrow biopsy showed acute lymphocytic leukemia.
 ...
PMID:Acute lymphocytic leukemia presenting as lupus-like syndrome. 1613 12

Lupus-like syndrome is characterized by multiple organ injuries including lungs and kidneys. Endotoxin induces a transiently intent systemic inflammatory response and indirectly transient acute lung injury in normal condition. However, whether endotoxin may trigger the persistent development of lung injury in chronic, inflammatory lupus-like syndrome compared with normal condition remains unclear. We examined the pulmonary vascular permeability and production of proinflammatory cytokines, such as TNF-alpha, IL-6, IL-10 and IFN-gamma, which play prominent roles in the pathogenesis of lupus-like tissue injury, 6 h and 72 h after i.p. lipopolysaccharide (LPS; endotoxin) injection in pristane-primed chronic inflammation ICR mice characterized by a lupus-like syndrome. These results demonstrated that levels of serum IL-6, IL-10 and IFN-gamma and bronchoalveolar lavage (BAL) IL-6 and IFN-gamma were remarkably increased 6 h in LPS-exposed pristane-primed mice compared with pristane-primed controls, while pulmonary vascular permeability and levels of serum and BAL TNF-alpha were not. And levels of BAL TNF-alpha, IL-6 and IL-10 were significantly enhanced 72 h in LPS-exposed pristane-primed mice compared with pristane-primed controls. Also, LPS significantly induced the increased in vitro production of TNF-alpha, IL-6 and IL-10 by lung cells obtained from LPS-exposed pristane-primed mice compared with LPS-exposed normal mice. Our findings indicate that LPS may trigger persistent progression of lung injury through late overproduction of BAL TNF-alpha, IL-6, and IL-10 in lupus-like chronic inflammation syndrome compared with normal condition.
 ...
PMID:Endotoxin induces late increase in the production of pulmonary proinflammatory cytokines in murine lupus-like pristane-primed model [corrected]. 1668 Oct 36

Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which developed following the 4th infliximab infusion in a 62-year-old patient with ankylosing spondylitis (AS). As far as we acknowledge, the present case is the third AS case with infliximab-induced lupus.
 ...
PMID:Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. 1871 23

Biologics are very useful medications that changed the lives of many patients in the last decade. However, we still do not know about the long-term side effects of these drugs. Infliximab is an anti-TNF chimeric antibody widely used and approved for the treatment of many diseases. Lupus-like syndrome and hepatitis are among the uncommon side effects of infliximab. Most of the written literature was published for cases of rheumatology and gastroenterology. We report here a case of both hepatitis and lupus-like syndrome that occurred sequentially in the same patient and compare our finding with two case reports of the same side effects, drug and disease.
...
PMID:Hepatitis and Lupus-Like Syndrome during Infliximab Therapy for Psoriasis. 2401 74